Biocytogen signs antibody license agreement with Pheon Therapeutics
Biocytogen Pharmaceuticals, a global biotech firm specialising in novel antibody therapeutics, has agreed to a licensing deal with Pheon Therapeutics, an antibody-drug conjugate (ADC) developer. Pheon Therapeutics is set to develop and commercialize an antibody created with Biocytogen Pharmaceuticals’ exclusive RenMice platforms, a technology that generates fully human antibodies with low immunogenicity, high diversity, species […]